FGFrancesca Ghilascu

Francesca Ghilascu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesca Ghilascu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatic Encephalopathy and Chronic Cerebrovascular Dysfunction (synthesis article)

    by Daniel Mocan, Francesca GhilașCu, Anastasia Comerzan, Diana Foiu, Diana Ciobanu, Daria Grigoreț, Adriana Botezatu, Nicolae Bodrug

    Hepatic encephalopathy (HE) is a frequent and disabling complication of liver cirrhosis and chronic liver failure. While traditionally attributed primarily to hyperammonemia, growing evidence indicates that HE results from the interaction of metabolic disturbances, systemic inflammation, intestinal dysbiosis, and cerebrovascular dysfunction, supporting its reconceptualization as a chronic brain disorder. A narrative review of the international literature published between 2000 and 2025 was conducted using PubMed/Medline, Journal of Hepatology, SpringerLink, and Google Scholar. Human studies relevant to the pathophysiology, diagnosis, and management of hepatic encephalopathy - including randomized controlled trials, observational studies, meta-analyses, and international guidelines - were included and synthesized qualitatively. Contemporary evidence supports an integrative gut-liver-brain model in which hyperammonemia acts synergistically with systemic inflammation, microbiome alterations, and blood-brain barrier dysfunction. These mechanisms converge to induce neuroinflammation, astrocytic dysfunction, and impaired cerebral blood flow autoregulation. Clinically, HE manifests across a broad cognitive, behavioral, and neuromotor spectrum, including minimal and covert forms associated with significant functional impairment. Cerebrovascular dysfunction appears to contribute to persistent cognitive deficits even after metabolic correction. Hepatic encephalopathy should be conceptualized as a metabolic-inflammatory-vascular brain disorder. While established therapies targeting ammonia and precipitating factors remain fundamental, emerging adjunctive approaches aimed at modulating inflammation, microbiome composition, and cerebral microcirculation warrant further investigation within rigorously designed clinical trials.

  • Open Access

    The Importance of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)

    by Daniel Mocan, Francesca Ghilascu, Anastasia Comerzan, Anastasia Pascalova, Adriana Botezatu, Nicolae Bodrug

    Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. It is recognized as a systemic disorder, involving airflow limitation, persistent inflammation, oxidative stress, and vascular dysfunction. Pulmonary hypertension (PH) is a clinically relevant and often underdiagnosed complication, impacting prognosis, functional capacity, and survival. Recent evidence shows that PH in COPD can develop early, even in moderate disease, and is associated with pulmonary vascular remodeling, endothelial dysfunction, and systemic inflammation. Distinct phenotypes, including disproportionate PH-COPD forms, exhibit severe hemodynamic impairment and poor outcomes. This review critically synthesizes current literature on the epidemiology, pathophysiology, clinical relevance, and therapeutic strategies for PH-COPD. Emerging complementary approaches targeting oxidative stress, inflammation, and endothelial dysfunction, including medical ozone therapy, are also discussed.

  • Open Access

    Autohemoterapia hiperbară cu ozon în esofagul Barrett asociat infecției cu Helicobacter pylori: studiu clinic comparativ, controlat, longitudinal

    by Nicolae Bodrug, Viorel Istrate, Adriana Botezatu, Marcela Dragomir, Marcel Covalciuc, Daniel Mocan, Victoria Țurcan, Francesca GhilașCu

    Barrett’s Esophagus (BE) is a precancerous esophageal condition often associated with chronic gastroesophageal reflux, while the role of Helicobacter pylori (H. pylori) infection in its progression remains controversial. Oxidative stress and chronic inflammation are key factors in the advancement of esophageal metaplasia. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) emerges as a promising adjuvant therapeutic option due to its antioxidant and immunomodulatory effects. This study included 60 patients with BE and active H. pylori infection, randomized into two equal groups: one treated with standard therapy combined with AHT-O₃, and one receiving standard therapy alone. Over a 12-month period, clinical, endoscopic, histological, and paraclinical evaluations were performed, including markers of oxidative stress, immunophenotyping, H. pylori infection status, CRP levels, GIQLI scores, and the dynamics of esophageal lesions. Ozone therapy led to a significant reduction in the oxidative stress marker malondialdehyde (MDA) and a notable increase in antioxidant enzymes (SOD, GPx, GST), indicating a restoration of redox balance. Concurrently, a significant increase in T-helper cells and a decrease in inflammatory T cells were observed, reflecting a favorable immune response. Parameters specific to H. pylori infection (IgA, IgG, fecal antigen) showed a more pronounced reduction in the ozone treatment group, indicating superior eradication efficiency. CRP levels decreased significantly, and GIQLI scores revealed a marked improvement in the quality of life. Endoscopic and histological assessments demonstrated a significantly higher rate of complete or partial regression of Barrett’s lesions in the ozone-treated group. Hyperbaric ozone autohemotherapy, when integrated into the standard therapeutic regimen, proved effective in counteracting oxidative stress, modulating immune responses, and significantly improving the clinical and histological status of patients with BE and H. pylori infection. These results support the use of this method as a complementary therapeutic strategy with added value in gastroenterology.

  • Therapeutic and Immunological Effects of Systemic Ozone Therapy in Atrophic Gastritis with Active Helicobacter pylori Infection

    by Adriana Botezatu, Nicolae Bodrug, Gabriel-Ioan Prada, Marcel Covalciuc, Marcela Dragomir, Leonid Chislaru, Victoria Turcan, Daniel Mocan, Francesca Ghilascu

    Atrophic gastritis is a precancerous lesion frequently associated with active Helicobacter pylori infection, representing a major risk factor for gastric cancer. The present controlled and longitudinal study evaluated the efficacy of ozone hyperbaric autohemotherapy (AHT-O₃) as an adjuvant treatment. The group of 60 patients was divided into two equal groups: standard treatment and standard treatment + AHT-O₃. At 12 months, the H. pylori eradication rate was 96% in the AHT-O₃ group, compared to 73% in the control group. Also, ozone-treated patients showed a decrease in malondialdehyde (from 4.5 to 2.2 nmol/ml) and an increase in SOD (from 150 to 210 U/ml). Immunologically, the proportion of T helper lymphocytes increased by 14%, and mucosal inflammation was reduced. Endoscopically, 47% of ozone-treated patients showed normalization of the gastric mucosa. The therapy was well tolerated, without adverse reactions. The results support the integration of ozone therapy into the complex management of HP-positive atrophic gastritis, especially in cases resistant to standard treatment.

  • Helicobacter pylori Infection - Associated Intestinal Metaplasia: A Comparative, Controlled, Longitudinal Clinical Study on the Efficacy of Hyperbaric Ozone Autohemotherapy

    by Adriana Botezatu, Nicolae Bodrug, Gabriel-Ioan Prada, Marcel Covalciuc, Francesca Ghilascu, Daniel Mocan, Victoria Turcan

    Gastric intestinal metaplasia is a precancerous lesion frequently associated with chronic H.pylori infection, representing a key stage in the gastric carcinogenesis cascade. Although bacterial eradication reduces the risk of progression to gastric adenocarcinoma, the efficacy of standard treatment in reversing intestinal metaplasia remains limited, particularly in extensive or incomplete forms. In this context, hyperbaric ozone autohemotherapy (AHT-O₃) is proposed as a therapeutic adjuvant with antioxidant, anti-inflammatory and immunomodulatory potential. This comparative, controlled and longitudinal clinical study evaluated the efficacy of AHT-O₃ combined with conventional therapy in 60 adult patients diagnosed with intestinal metaplasia and active H.pylori infection. The AHT-O₃-treated group showed a significant reduction in malondialdehyde (MDA) levels and an increase in the activity of antioxidant enzymes (SOD, GPx, GST), compared to the control group (p less than 0.001). Additionally, a stimulation of T-helper lymphocytes and a decrease in pro-inflammatory lymphocytes were observed, indicating a robust immunoregulatory effect. The H.pylori eradication rate was higher in the ozone group (84% vs. 60%, p = 0.04), with a significantly greater decrease in IgA and IgG titers (p less than 0.01). Endoscopic and histological evaluation after 12 months showed an increased rate of complete and partial regression of intestinal metaplasia lesions and a marked reduction in gastric mucosal inflammation. The GIQLI score indicated a significant improvement in quality of life in the ozone-treated group. These results support the inclusion of AHT-O₃ as a viable complementary option in the therapeutic strategy for H.pylori-associated intestinal metaplasia, with a positive impact on the clinical, biochemical, and histological progression of the condition.